Jiangkamp0346

7% after five treatment cycles in real wastewater, showing good potential in practical application. We believe this study sheds light on the tailored design of Fenton-like catalysts and elucidates the catalytic mechanisms of supported bimetallic catalysts.BACKGROUND This study aimed to identify differences in prognosis, causes of death, and outcomes between open and endovascular repair for aortic arch aneurysms. METHODS We retrospectively analyzed the survival status and causes of death determined from the medical records of 124 consecutive elderly patients (age > 70 years) with aortic arch aneurysms that were treated between 2010 and 2018 at our hospital. Forty patients (male, n = 30; mean age, 76 years) underwent open repair and 84 (male, n = 68; mean age, 78 years) underwent endovascular repair. RESULTS Early postoperative complications (10.0% vs. 6.3%; P = 0.4) and rates of in-hospital death (2.5% vs. 6.3%; P = 0.2) did not significantly differ between open and endovascular repair. Cumulative long-term and event free survival rates at eight years were similar in both groups (78.7% vs. 66.3%, P = 0.1 and 66.6% vs. 58.4%; P = 0.4, respectively). The causes of death at follow-up after endovascular repair comprised malignancies in 11 (52.4%) patients and cardiopulmonary and cerebral events unrelated to aortic aneurysms in 10 (47.6%). CONCLUSIONS Early and late outcomes did not statistically differ after both procedures. However, the prevalence of cancer-related death occurring late after arch repair was significantly higher after endovascular repair. The most important observation from this series was that significantly more patients died of malignant disease during follow-up after endovascular repair than open repair.BACKGROUND We aimed to study prospectively the nature and effect of sleep apnea-hypopnea syndrome (SAHS) in patients undergoing coronary artery bypass graft (CABG) surgery over five years of follow-up. METHODS Patients undergoing CABG surgery (n=145) were assessed longitudinally (baseline, and 1- year, 5-years post-surgery) using the 'STOP-BANG' screen of sleep apnoea risk. Additionally, all patients had a pre-operative multiple-channel sleep-study, providing acceptable data for an obstructive and central apnea, and desaturation index in 97 patients. RESULTS Pre-operatively, over half (63%) of patients obtained an apnea-hypopnea index score (combining apnea types) in the moderate-severe range for SAHS, and STOP-BANG threshold score (>3/8) was reached by most (95%) patients. Despite some improvement in 'STOP symptoms' at 1- year follow-up, most patients (98%) remained at risk of SAHS at 5-years post-surgery. There was an underlying and chronic relationship between STOP-BANG score and cardiac symptoms at both baseline and 5-year follow-up. Superimposed on this, SAHS variables were associated with greater incidence of acute post-operative events, and generally with increased length of stay on the intensive care unit. CONCLUSIONS We confirm that SAHS is common in CABG-surgery patients, presenting additional clinical challenges and cost implications. The underlying pathophysiology is complex, including upper airway obstruction and cardiorespiratory changes of heart failure. In patients presenting for CABG-surgery, we show chronic susceptibility to SAHS, likely associated with traditional risk factors e.g. obesity but perhaps also with gradual decline in heart function itself. Superimposed on this, there is potential for exacerbated risk of morbidity at the time of CABG surgery itself.INTRODUCTION Previously, the American College of Obstetrics and Gynecology (ACOG) had published an excellent practice bulletin addressing the use of hormone contraception in women with pre-existing medical conditions. This practice bulletin became out of date. The Centers for Disease Control and prevention (CDC) of the United States subsequently developed a point form guideline for the use of oral contraceptives in women with co-existing medical conditions. EVIDENCE ACQUISITION Although this acts as a guide, it leaves the clinician without an understanding of why they are doing what they are doing. learn more This article, is one of two related to women with co-existing medical conditions. EVIDENCE SYNTHESIS In this article we will provide an update of the scientific knowledge since the publication of the ACOG guideline (2006). It is to be used as a supplement for those who desire more information than is found in the CDC guidelines. CONCLUSIONS Although some recommendations have remained unchanged over the years, the development of lower dose contraceptive pills as well as the increased incidence of comorbid conditions, such as metabolic syndrome, in younger women seeking contraception has brought along new research and new evidence to guide clinicians in the prescription of these medications.INTRODUCTION The Centers for Disease Control and Prevention (CDC) developed a point form guideline for the use of oral contraceptives in women with co-existing medical conditions. Although this acts as a guide, it leaves the clinician without an understanding of why they are doing what they are doing. EVIDENCE ACQUISITION In this article, which is one of two articles addressing co-existing medical condition and oral contraceptive use, an update of the scientific knowledge is provided. EVIDENCE SYNTHESIS The explanation of the guidelines are to be used as a supplement for those who desire more information than is found in the CDC guidelines and in general a review for clinicians dealing with women desiring hormonal contraception. CONCLUSIONS The development of lower dose contraceptive pills as well as the increased incidence of comorbid conditions, such as metabolic syndrome, in younger women seeking contraception has brought along new research and new evidence to guide clinicians in the prescription of these medications.BACKGROUND Medication adherence is a determinant of therapeutic outcomes in patients with osteoporosis treated with bisphosphonates. In this monocentric study, we evaluated whether the regular drug administration may influence the effectiveness of denosumab in preventing vertebral fractures (VFs) in real-world clinical practice. METHODS Two-hundred-four women (median age 75 years, range 54-90) under treatment with denosumab for post-menopausal osteoporosis were longitudinally evaluated for incident radiological VFs and changes in lumbar spine bone mineral density (BMD) in relationship with medication adherence. All patients were persistent with denosumab treatment (i.e., maximum delay in administration of a single denosumab dose 90 days). Patients were defined adherent to denosumab therapy when the drug was administered every 6 months±28 days. RESULTS One-hundred-seventy-three patients (84.4%) were adherent to denosumab therapy, whereas the remaining 31 patients (15.6%) received in delay one or more denosumab doses (cumulative delay 52 days, range 29-183).